Kanchan Shah¹, Bhavana Valvi²*, Prashant Pandilwar³, Suraj Parmar² and Wahab Shaikh¹

¹Associate Professor, Department of Oral and Maxillofacial Surgery, Government Dental College and Hospital, Aurangabad, Maharashtra, India

*Corresponding Author: Bhavana Valvi, Assistant Professor, Department of Oral and Maxillofacial Surgery, Government Dental College and Hospital, Nagpur, Maharashtra, India.

Received: October 20, 2021; Published: December 09, 2021

Abstract

Post COVID Mucormycosis is declared epidemic in India after 2^nd wave. Corticosteroids are widely use in the management of COVID 19, which causes tremendous immunosuppression and gives birth to various opportunistic bacterial and viral infections like, Mucormycosis which is a lethal or deadly infection which kills the patient or made the person physically handicapped. Mucormycosis is common in maxilla and rare in mandible. We are presenting a case report of a 55 years old male patient having post COVID Mucormycosis along with osteomyelitis of the mandible, the rarest form of the post COVID infection, which was managed surgically as well as with adjuvant medicinal management followed by post-operative prosthetic rehabilitation.

Keyword: Post COVID Mucormycosis; Osteomyelitis

References

1. Sharma S., et al. "Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum”. The Journal of Laryngology and Otology5 (2021): 442-447.
2. Bhatt Kinal., et al. "High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections”. Discoveries1 (2021).
3. Dilek A., et al. "COVID-19-associated mucormycosis: Case report and systematic review”. Travel Medicine and Infectious Disease 26) (2021): 102148.
4. A Paultauf. “Mycosismucorina”. Virchow’s Archiv fur Pathologische Anatomie und Physiologie und fur klinische Medicin 102 (1985): 543-564.
5. Arastehfar Amir., et al. "COVID-19 associated pulmonary aspergillosis (CAPA)—from immunology to treatment”. Journal of Fungi2 (2020): 91.
6. Rao Eswar., et al. (2015).
7. Kimmig Lucas M., et al. "Il-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections”. Frontiers in Medicine7 (2020): 689.
8. Artis William M., et al. "A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis transferrin and iron availability”. Diabetes12 (1982): 1109-1114.
9. Khudyakov Aleksandr., et al. "A Rare Indolent Course of Rhinocerebral Mucormycosis”. Case Reports in Infectious Diseases2021 (2021).
10. Thom Stephen R. "Analytic reviews: hyperbaric oxygen therapy”. Journal of Intensive Care Medicine2 (1989): 58-74.
11. Oswal Nitin Prakash., et al. "Mucormycosis of mandible with unfavorable outcome”. Case Reports in Dentistry2012 (2012).
12. Pasero Daniela., et al. "A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis”. Infection5 (2021): 1055-1060.
13. Kimmig Lucas M., et al. "Il-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections”. Frontiers in medicine7 (2020): 689.
14. Garg Deepak., et al. "Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature”. Mycopathologia (2021): 1-10.
15. Muthu Valliappan., et al. "The reversed halo sign and the bronchus sign: the eyes see only what the mind knows”. Annals of the American Thoracic Society9 (2019): 1203-1203.

Citation

Citation: Bhavana Valvi., et al. “Post Covid 19 - Mucormycosis and Osteomyelitis of the Mandible- A Rare Case Report". Acta Scientific Otolaryngology 4.2 (2022): 18-22.

Copyright

Copyright: © 2022 Bhavana Valvi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.